DALLAS – February 17, 2026 – A new study from UT Southwestern Medical Center is reshaping how researchers understand KRAS, a gene frequently mutated in many cancers. The research, published in Science Translational Medicine, suggests that different types of KRAS mutations impact how cancer cells interact with the immune system, potentially opening the door to more personalized and effective cancer treatments. For years, KRAS mutations were largely considered to drive cancer in a uniform way, but this study demonstrates a more nuanced picture, particularly in lung adenocarcinoma.
The findings center on two common KRAS mutations: G12C and G12D. While both contribute to cancer development, researchers discovered they elicit different responses from the body’s immune defenses. This distinction is crucial because it explains why some patients respond better to immunotherapy – treatments designed to harness the immune system to fight cancer – than others. Understanding these differences in KRAS mutations could lead to more targeted therapies and improved outcomes for patients with KRAS-driven cancers.
Distinct Immune Responses to Different KRAS Mutations
Up to a third of patients diagnosed with lung adenocarcinoma, the most prevalent form of lung cancer, carry a KRAS mutation. Approximately 41% of these patients have the G12C mutation, while 17% have the G12D mutation. Researchers, led by Esra Akbay, Ph.D., Associate Professor of Pathology at UT Southwestern, found that tumors with the G12D mutation grow and spread more rapidly than those with the G12C mutation. Experiments with mice mirrored these observations, showing significantly shorter survival times in mice with the G12D mutation.
“Rather than treating KRAS as a single entity, this study reframes the field by asking a more precise question: ‘Which KRAS mutation?’ We show that different mutation types create distinct tumor ecosystems that can have real effects on patient outcomes,” Dr. Akbay explained. The team’s investigation revealed that tumors harboring the G12C mutation exhibited greater activity in genes associated with inflammation and immune response. These tumors contained a higher concentration of immune cells, including lymphocytes and cytotoxic T cells, and expressed more PDL1 – a protein that can be targeted by immune checkpoint inhibitors.
Implications for Immunotherapy and Targeted Therapies
The study’s findings have significant implications for how cancer treatments are approached. Currently, immune checkpoint inhibitors have shown limited success in treating cancers with the G12D mutation. The research suggests this is because these tumors are less visible to the immune system. However, when mice with the G12D mutation were treated with a drug specifically targeting that mutation, their tumors began to exhibit characteristics similar to those with the G12C mutation – increased antigen presentation, higher PDL1 production, and a greater influx of immune cells.
Remarkably, combining the G12D-targeting drug with an immune checkpoint inhibitor led to complete tumor eradication in many of the mice. This suggests a potential therapeutic strategy: first, target the specific KRAS mutation to “prime” the tumor, making it more susceptible to immune attack, and then unleash the immune system with an immune checkpoint inhibitor. This approach could be particularly beneficial for patients whose cancers have historically been resistant to immunotherapy.
Beyond Lung Cancer: A Broader Impact
While the initial research focused on lung adenocarcinoma, the implications extend to other cancers driven by KRAS mutations. KRAS is the most frequently mutated oncogene across all human cancers, including pancreatic cancer and colorectal cancer. The UT Southwestern team’s work highlights the importance of understanding the specific KRAS mutation present in a patient’s tumor to tailor treatment strategies effectively.
Other researchers who contributed to the study included Hai-Cheng Huang, Ph.D., and Qing Deng, Ph.D., both from the Akbay Lab; Luis De Las Casas, M.D., Professor of Pathology; Lin Xu, Ph.D., Assistant Professor in the Peter O’Donnell Jr. School of Public Health and of Pediatrics; and Lei Guo, Ph.D., Computational Biologist. Dr. Akbay is also a member of the Simmons Cancer Center’s Development and Cancer Research Program.
Looking Ahead
The research was supported by grants from the Cancer Prevention and Research Institute of Texas (CPRIT), the National Institutes of Health (NIH), the National Cancer Institute (NCI), the American Cancer Society, the Forbeck Foundation, and the NCI Cancer Center Support Grant. Future research will focus on validating these findings in larger patient cohorts and exploring the potential of combination therapies targeting specific KRAS mutations and bolstering the immune response. The ultimate goal is to develop personalized treatment plans that maximize the effectiveness of cancer therapies and improve outcomes for patients with KRAS-driven cancers.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
This groundbreaking research offers a hopeful step forward in the fight against cancer. If you have questions about KRAS mutations or cancer treatment options, please consult with your healthcare provider. Share this article with others who may benefit from this information.
